CAJ | 학술논문

伊立替康是治疗胃肠道肿瘤和小细胞肺癌的常用化疗药物，其最常见的不良反应为迟发性腹泻和中性粒细胞减少。不良反应的发生与遗传因素和非遗传因素有关。遗传因素涉及羧酸酯酶、肝脏尿苷二磷酸葡萄糖醛酸转移酶1A和细胞色素P4503A4等多种酶与转运体的基因多态性。患者的年龄、吸烟、合并用药等非遗传因素也可影响机体对伊立替康的敏感性和药物在体内的代谢过程。针对不同基因型患者制定伊立替康的个体化治疗方案，有助于提高临床疗效并降低不良反应发生率。
이립체강시치료위장도종류화소세포폐암적상용화료약물，기최상견적불량반응위지발성복사화중성립세포감소。불량반응적발생여유전인소화비유전인소유관。유전인소섭급최산지매、간장뇨감이린산포도당철산전이매1A화세포색소P4503A4등다충매여전운체적기인다태성。환자적년령、흡연、합병용약등비유전인소야가영향궤체대이립체강적민감성화약물재체내적대사과정。침대불동기인형환자제정이립체강적개체화치료방안，유조우제고림상료효병강저불량반응발생솔。
Irinotecan is a chemotherapeutic agent widely used in the treatment of gastrointestinal cancer and small cell lung cancer. The common adverse reactions of irinotecan are delayed onset diarrhea and neutropenia. These adverse reactions are associated with genetic factors and non-genetic factors. Genetic factors include genetic polymorphisms of various enzymes and transporters,such as carboxylesterase,liver uridine diphosphate glucuronosyltransferase 1A,and cytochrome P450 3A4. Non-genetic factors including age,smoking,and drug combination can also affect the susceptibility of irinotecan and metabolism of drugs. Providing an individualized treatment according to different genotypes can improve clinical response of irinotecan and decrease the incidence of adverse reactions.